<DOC>
	<DOCNO>NCT02909400</DOCNO>
	<brief_summary>Mitochondrial Diseases rare , progressive , multi-system , often-early fatal disorder affect child adult . KH176 novel chemical entity currently development treatment inherit mitochondrial disease , include MELAS ( Mitochondrial Encephalomyopathy , Lactic acidosis , Stroke-like episode ) , MIDD ( Maternally Inherited Diabetes Deafness ) , Leigh 's Disease LHON ( Leber 's Hereditary Optic Neuropathy ) . The current Proof Concept study aim explore effect treatment KH176 4 week clinical sign symptom biomarkers mitochondrial disease evaluate safety pharmacokinetics KH176 patient m.3242A &gt; G relate mitochondrial disease .</brief_summary>
	<brief_title>The KHENERGY Study</brief_title>
	<detailed_description>The trial double blind , randomize , placebo-controlled , single-centre , two-way cross-over trial . Twenty patient , confirm mitochondrial DNA tRNALeu ( UUR ) m.3243A &gt; G mutation clinical sign mitochondrial disease , randomize 2 group ( active placebo first ) . After screen period training session , group 2 dose period 28 day , washout period least 28 day . On occasion , patient receive 100 mg KH176 twice daily ( treatment A ) match placebo ( treatment B ) twice daily 28 day . Clinical assessment perform training session prior baseline , baseline week 4 post dosing treatment phase ( A B ) . Testing condition circumstance , respect timing assessment , hospitalization meal , standardized assessement period . Furthermore , assessments biomarkers mitochondrial functioning , pharmacokinetics specific safety assessment perform weekly .</detailed_description>
	<mesh_term>Mitochondrial Diseases</mesh_term>
	<mesh_term>Mitochondrial Myopathies</mesh_term>
	<mesh_term>Mitochondrial Encephalomyopathies</mesh_term>
	<criteria>1 . Males female age 18 year old screen 2 . Ability willingness sign Informed Consent Form prior screen evaluation . 3 . Confirmed mitochondrial DNA tRNALeu ( UUR ) m.3243A &gt; G mutation 4 . Heteroplasmy level measure urine â‰¥ 20 % . 5 . Body Mass Index ( BMI ) 18.030.0 kg/m2 ( extremes include ) screen 6 . Clinical evidence mitochondrial disease , positive NMDAS score ( include limit MELAS , MIDD mixed type ) . CPEO patient sign restrict eye consider eligible . 7 . Disease appropriate physical mental health establish medical history , physical examination , electrocardiogram ( ECG ) vital sign record , result biochemistry , hematology urinalysis test within 3 week prior first dose judged Investigator . 8 . Appropriate cardiac functioning assess medical history , ECG Echo , evaluate cardiologist . 9 . Able comply study requirement , include exercise test swallow study medication 10 . Willingness use adequate contraceptive method ( male female ) negative urine pregnancy test ( female ) screen first baseline assessment . 11 . Able willing refrain use ( multi ) vitamins , coenzyme Q10 , Vitamine E , riboflavin , antioxidant supplement ( idebenone/EPI743 ) , well medication negatively influence mitochondrial functioning ( include limit valproic acid , glitazones , statin , antiviral , amiodarone , NSAID 's ) well strong Cytochrome P450 inhibitor ( 'conazolesantifungals ' , HIV antiviral , grapefruit ) strong Cytochrome P450 inducer ( a.o . carbamazepine , phenobarbital , phenytoin , rifampicine , St Johns wort , pioglitazone , troglitazone ) well medication know affect cardiac repolarization ( antipsychotic , several antidepressant : nor/amytriptilline , fluoxetine , antiemetic : domperidone ( motilium ) granisetron , ondansetron ) . 1 . Motoric abnormality relate mitochondrial disease interfere outcome parameter . 2 . CPEO patient clinical sign symptom restrict eye 3 . Heteroplasmy level measure urine &lt; 20 % 4 . Poor nutritional state judge investigator 5 . Body Mass Index ( BMI ) within 18.030.0 kg/m2 screen . 6 . History cancer 7 . Surgery active illness gastrointestinal tract might interfere absorption . 8 . Participation trial investigational product precede 3 month prior first dose trial . 9 . Positive drug , alcohol cotinine test screen and/or admission ( Day 1 first dose period ) . 10 . Clinically relevant abnormal laboratory , ECG recording , cardiac echo ( within 1 year prior screen ) , vital sign physical mental finding screen judged Investigator . 11 . Clinically relevant abnormal ECG cardiac function judged cardiologist . 12 . ECG : QTc &gt; 450 m , abnormal Twave 13 . Symptomatic heart failure sign ischemic heart disease 14 . Left Ventricular Ejection Fraction &lt; 45 % 15 . History family history congenital Long QT syndrome 16 . Increased decreased potassium ( local laboratory normal range ) 17 . Inadequate contraception use , pregnancy breast feeding ( female ) 18 . Clinically significant presence history allergy judge Investigator . 19 . History hypersensitivity idiosyncrasy component investigational drug . 20 . Within 4 week prior dose , use : ( multi ) vitamins , coenzyme Q10 , Vitamine E , riboflavin , antioxidant supplement ( idebenone/EPI743 ) , well medication negatively influence mitochondrial functioning ( include limit valproic acid , glitazones , statin , antiviral , amiodarone , NSAID 's ) well strong Cytochrome P450 inhibitor ( 'conazolesantifungals ' , HIV antiviral , grapefruit ) strong Cytochrome P450 inducer ( a.o . carbamazepine , phenobarbital , phenytoin , rifampicin , St Johns wort , pioglitazone , troglitazone ) well medication know affect cardiac repolarization ( antipsychotic , several antidepressant : nor/amitriptyline , fluoxetine , antiemetic : domperidone ( motilium ) granisetron , ondansetron ) well medication metabolize Cytochrome P450 narrow therapeutical width . ( reference : drug interaction table Indiana University http : //medicine.iupui.edu/clinpharm/ddis/clinicaltable/ )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>mitochondrial</keyword>
	<keyword>oxidative phosphorylation ( oxphos )</keyword>
	<keyword>MELAS</keyword>
	<keyword>MIDD</keyword>
	<keyword>KH176</keyword>
	<keyword>Proof Concept</keyword>
</DOC>